Results 81 to 90 of about 1,264,620 (412)

The cytoskeletal control of B cell receptor and integrin signaling in normal B cells and chronic lymphocytic leukemia

FEBS Letters, EarlyView.
In lymphoid organs, antigen recognition and B cell receptor signaling rely on integrins and the cytoskeleton. Integrins act as mechanoreceptors, couple B cell receptor activation to cytoskeletal remodeling, and support immune synapse formation as well as antigen extraction.
Abhishek Pethe, Tanja Nicole Hartmann
wiley   +1 more source

Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel

Journal of Hematology & Oncology
Bendamustine has been retrospectively shown to be an effective and safe lymphodepletion regimen prior to the anti-CD19 chimeric antigen receptor T cell (CART) products tisagenlecleucel and axicabtagene ciloleucel, as well as the anti-BCMA CART products ...
Guido Ghilardi, Luca Paruzzo, Vrutti Patel, Jakub Svoboda, Emeline R. Chong, Eugenio Fardella, Elise A. Chong, Giulia Gabrielli, Sunita D. Nasta, Daniel J. Landsburg, Jordan Carter, Raymone Pajarillo, Stefan K. Barta, Griffin White, Elizabeth Weber, Ellen Napier, David L. Porter, Alfred L. Garfall, Stephen J. Schuster, Marco Ruella   +19 more
doaj   +1 more source

Origin and pathogenesis of nodular lymphocyte–predominant Hodgkin lymphoma as revealed by global gene expression analysis [PDF]

, 2008
The pathogenesis of nodular lymphocyte–predominant Hodgkin lymphoma (NLPHL) and its relationship to other lymphomas are largely unknown. This is partly because of the technical challenge of analyzing its rare neoplastic lymphocytic and histiocytic (L&H ...
Brune, Verena, Bräuninger, Andreas, Döring, Claudia, Eckerle, Susan, Falini, Brunangelo, Hansmann, Martin-Leo, Heydebreck, Anja von, Klapper, Wolfram, Küppers, Ralf, Metzler, Dirk, Pfeil, Ines, Tiacci, Enrico, van Noesel, Carel J. M.   +12 more
core   +1 more source

BREAST LYMPHOMA

, 2023
Primary breast lymphoma is a very rare histological entity of breast cancer. The Clinical and radiological aspects do not present any particular specificities. Diagnosis is often delayed. The treatment is mainly based on chemotherapy. We report the case of a patient with high grade malignant non-Hodgkin lymphoma.
Marrakchi Benjaafar M. Hamza, Kaoutar Soussy, Sara Yacoubi Khebiza, M. Abdelilah Melhouf, , Zineb Alami And Touria Bouhafa   +2 more
openaire   +4 more sources

Surfaceome: a new era in the discovery of immune evasion mechanisms of circulating tumor cells

Molecular Oncology, EarlyView.
In the era of immunotherapies, many patients either do not respond or eventually develop resistance. We propose to pave the way for proteomic analysis of surface‐expressed proteins called surfaceome, of circulating tumor cells. This approach seeks to identify immune evasion mechanisms and discover potential therapeutic targets. Circulating tumor cells (
Doryan Masmoudi, Jérome Vialaret, Christophe Hirtz, Catherine Alix‐Panabières   +3 more
wiley   +1 more source

Convolutional neural network with a hybrid loss function for fully automated segmentation of lymphoma lesions in FDG PET images [PDF]

arXiv, 2022
Segmentation of lymphoma lesions is challenging due to their varied sizes and locations in whole-body PET scans. This work presents a fully-automated segmentation technique using a multi-center dataset of diffuse large B-cell lymphoma (DLBCL) with heterogeneous characteristics.
arxiv  

FNA based diagnosis of head and neck nodal lymphoma [Citomorfološka dijagnoza limfoma u području glave i vrata] [PDF]

, 2010
Fine-needle aspiration (FNA) biopsy has become a well established technique in the diagnosis, staging, and follow-up of patients with head and neck lesions.
Aurer, Igor, Bašić-Kinda, Sandra, Gjadrov Kuveždić, Koraljka, Ilić, Ivana, Labar, Boris, Marković Glamočak, Mirjana, Radman, Ivo, Ries, Sunčica, Sučić, Mirna   +8 more
core  

A Phase I/II first-line study of R-CHOP plus B-cell receptor/NF-κB-double-targeting to molecularly assess therapy response [PDF]

, 2019
The ImbruVeRCHOP trial is an investigator-initiated, multicenter, single-arm, open label Phase I/II study for patients 61-80 years of age with newly diagnosed CD20+ diffuse large B-cell lymphoma and a higher risk profile (International Prognostic Index ...
Anagnostopoulos, Ioannis, Bittner, Aitomi, Denker, Sophy, Frick, Mareike, Hummel, Michael, Kase, Julia, Na, Il-Kang, Schmitt, Clemens A.   +7 more
core   +2 more sources

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

New England Journal of Medicine, 2013
BACKGROUND Bruton's tyrosine kinase (BTK) is a mediator of the B-cell-receptor signaling pathway implicated in the pathogenesis of B-cell cancers. In a phase 1 study, ibrutinib, a BTK inhibitor, showed antitumor activity in several types of non-Hodgkin's
Michael L. Wang, S. Rule, P. Martin, A. Goy, R. Auer, B. Kahl, W. Jurczak, R. Advani, J. Romaguera, Michael E. Williams, J. Barrientos, E. Chmielowska, J. Radford, S. Stilgenbauer, M. Dreyling, W. Jędrzejczak, Peter W M Johnson, S. Spurgeon, Lei Li, L. Zhang, K. Newberry, Zhishuo Ou, N. Cheng, B. Fang, J. Mcgreivy, F. Clow, J. Buggy, B. Chang, D. Beaupre, L. Kunkel, K. Blum   +30 more
semanticscholar   +1 more source

Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients

Molecular Oncology, EarlyView.
Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha, Steven Kao, Veronica K. Cheung, Wendy A. Cooper, Nico van Zandwijk, John E. J. Rasko, Dannel Yeo   +6 more
wiley   +1 more source